MedPath

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

Completed
Conditions
Glioblastoma
Registration Number
NCT03770468
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are:

* Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1)

* Identification of molecular tumor characteristics in long-term survivors (Focus 2)

* Assessment of therapy-related parameters, including neuro-toxicity (Focus 3)

* Immunological studies (Focus 4)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
599
Inclusion Criteria
  • Age > 18 years at diagnosis
  • Histopathological diagnosis of glioblastoma (reference histology available) and
  • Survival >5 years from diagnosis
  • Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally.
  • Signed consent form (living patients) or ethics approval for anonymous data collection in case of retrospective analysis of deceased patients
Exclusion Criteria
  • Not applicable

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Molecular profiling on frozen samples1 year from last patient in

Samples will be subjected to microarray-based expression profiling

Molecular profiling on FFPE samples1 year from last patient in

Profiling for cytosine-phosphate-guanosine (CpG) methylation patterns using the Illumina 850k bead array platform

Overall Survival1 year from last patient in
Proteome profiling1 year from last patient in

Tumor cells will be microdissected from frozen sections and prepared for high-resolution mass spectrometry

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (27)

Dana-Farber Cancer Institute & Harvard Medical School

🇺🇸

Boston, Massachusetts, United States

Universitaetsklinikum Wien - AKH uniklinieken

🇦🇹

Vienna, Austria

Hopitaux Universitaires Bordet-Erasme

🇧🇪

Brussel, Belgium

CHU Lyon - Hopital neurologique Pierre Wertheimer

🇫🇷

Bron, France

CHRU de Lille

🇫🇷

Lille, France

Hopitaux de Marseille - Hôpital de La Timone (APHM)

🇫🇷

Marseille, France

Institut du Cancer de Montpellier

🇫🇷

Montpellier, France

CHU de Nice - Hopital Pasteur

🇫🇷

Nice, France

Hopitaux de Paris - Hopital Saint-Louis

🇫🇷

Paris, France

Hopitaux de Paris - La Pitie Salpetriere

🇫🇷

Paris, France

Scroll for more (17 remaining)
Dana-Farber Cancer Institute & Harvard Medical School
🇺🇸Boston, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.